A Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Varying Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2 Infection

Trial Profile

A Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Varying Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2 Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2016

At a glance

  • Drugs GEN 003 (Primary) ; Matrix M
  • Indications Herpes genitalis; Herpes simplex virus type 2 infections
  • Focus Pharmacodynamics
  • Sponsors Genocea Biosciences
  • Most Recent Events

    • 30 Oct 2016 Result of 1 year follow up assessing antibody response to GEN-003 and their correlation with viral shedding and lesion data presented at the IDWeek 2016
    • 28 Oct 2016 Results published in the Genocea Biosciences Media Release
    • 28 Sep 2016 12 month immunogenicity data from this trial presented at the Infectious Disease Society of America (IDSA) annual meeting, according to a Genocea Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top